Zosano Pharma Corp Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2021-12-13: Form 8-K; Period of report 2021-12-07; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2021-11-30: Form 8-K; Period of report 2021-11-30; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2021-11-17: Form 8-K; Period of report 2021-11-17; Description 8.01 Other Events; Details 8.01.
- 2021-11-10: Form 8-K; Period of report 2021-11-10; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2021-12-13 | 8-K | 2021-12-07 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 7, 2021, the Board of Directors (the “Board”) of Zosano Pharma Corporation (the “Company”) appointed Elaine Yang to serve as a member of the Board, effective immediately. | zsan-20211207.htm |
| 2021-11-30 | 8-K | 2021-11-30 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 As previously disclosed, on June 1, 2021, Zosano Pharma Corporation (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Listing Rule 5550(a)(2). | zsan-20211130.htm |
| 2021-11-17 | 8-K | 2021-11-17 | 8.01 Other Events | 8.01 On November 17, 2021, Zosano Pharma Corporation issued a press release announcing the successful formulation of a COVID-19 vaccine candidate on its microneedle patch system. | zsan-20211117.htm |
| 2021-11-10 | 8-K | 2021-11-10 | 2.02 Results of Operations and Financial Condition | 2.02 On November 10, 2021, Zosano Pharma Corporation issued a press release titled “Zosano Pharma Reports Third Quarter 2021 Financial Results.” The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. | zsan-20211110.htm |
| 2021-10-29 | 8-K | 2021-10-25 | 8.01 Other Events | 8.01 On October 25, 2021, Zosano Pharma Corporation (the “Company”) received full data tables from its pharmacokinetic study, which were consistent with the top-line results previously announced and reported in the Company’s current report on Form 8-K filed with the Securities and Exchange Commission on October 4, 2021. | d217705d8k.htm |
| 2021-10-06 | 8-K | 2021-10-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 (b) On October 5, 2021, Hayley Lewis, the Senior Vice President, Operations of Zosano Pharma Corporation (“Zosano” or the “Company”), notified the Company of her intent to resign effective October 22, 2021 to pursue an opportunity with another company. 8.01 The Company has refined its strategy for the resubmission of the M207 (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) following the Company’s receipt of top-line results from the pharmacokinetic study. | d212272d8k.htm |
| 2021-10-04 | 8-K | 2021-09-28 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On October 4, 2021, the Company announced that it has been granted a Type C written response only meeting with the U.S. Food and Drug Administration regarding the resubmission of the M207 (zolmitriptan transdermal microneedle system) 505(b)(2) NDA following receipt of preliminary top-line results from the pharmacokinetic study. | d203941d8k.htm |
| 2021-08-10 | 8-K | 2021-08-10 | 2.02 Results of Operations and Financial Condition | 2.02 On August 10, 2021, Zosano Pharma Corporation issued a press release titled “Zosano Pharma Reports Second Quarter 2021 Financial Results.” The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. | q22021earnings8-k.htm |
| 2021-07-02 | 8-K | 2021-06-30 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 30, 2021, Zosano Pharma Corporation (the “Company”) held its reconvened 2021 Annual Meeting of Stockholders (the “Annual Meeting”). | d143123d8k.htm |
| 2021-06-28 | 8-K | 2021-06-28 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 During the period from April 1, 2021 through June 9, 2021, the Company issued and sold 6,848,672 shares of common stock under its at-the-market offering program with BTIG, LLC (“BTIG”). | d175431d8k.htm |
| 2021-06-21 | 8-K | 2021-06-17 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure | 5.03 On and effective as of June 17, 2021, the Board of Directors (the “Board”) of Zosano Pharma Corporation (the “Company”) approved the amendment and restatement of the Bylaws of the Company (the “Amended and Restated Bylaws”) to reduce the quorum required for meetings of stockholders from a majority to one-third (1/3) of the outstanding shares of stock entitled to vote, present in person, by remote communication or by proxy, and further to provide that where a separate vote by a class or classes or series is required, except where otherwise provided by statute or by the Certificate of Incorporation or the Bylaws, one-third (1/3) of the outstanding shares of such class or classes or series entitled to vote, present in person, by remote communication or by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter. 7.01 As previously disclosed in the Company’s current report on Form 8-K filed with the SEC on June 10, 2021, on June 10, 2021, the Company convened and adjourned the 2021 Annual Meeting of Stockholders of the Company (the “Annual Meeting”) without any business being conducted, due to lack of the requisite quorum. | d195177d8k.htm |
| 2021-06-10 | 8-K | 2021-06-10 | 7.01 Regulation FD Disclosure | 7.01 On June 10, 2021, Zosano Pharma Corporation convened and adjourned its 2021 Annual Meeting of Stockholders (the “Annual Meeting”), without any business being conducted, due to lack of the requisite quorum. | d100486d8k.htm |
| 2021-06-01 | 8-K | 2021-06-01 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On June 1, 2021, Zosano Pharma Corporation (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Listing Rule 5550(a)(2). | d183713d8k.htm |
| 2021-05-25 | 8-K | 2021-05-24 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 24, 2021, the Board of Directors (the “Board”) of Zosano Pharma Corporation (the “Company”) appointed Kathy McGee to serve as a member of the Board, effective immediately. | d344157d8k.htm |
| 2021-05-12 | 8-K | 2021-05-12 | 2.02 Results of Operations and Financial Condition | 2.02 On May 12, 2021, Zosano Pharma Corporation issued a press release titled “Zosano Pharma Reports First Quarter 2021 Financial Results.” The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. | zsan-20210512.htm |
| 2021-04-26 | 8-K | 2021-04-26 | 8.01 Other Events | 8.01 On April 26, 2021, Zosano Pharma Corporation (the “Company”) announced that the Company established an agreement with Worldwide Clinical Trials to conduct the pharmacokinetic study required to support the resubmission of the Qtrypta™ (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application (“NDA”). | d94568d8k.htm |
| 2021-04-13 | 8-K | 2021-04-12 | 8.01 Other Events | 8.01 On April 12, 2021, Zosano Pharma Corporation (the “Company”) received U.S. Food and Drug Administration comments and recommendations to the Company’s proposed pharmacokinetic (PK) study protocol for Qtrypta™. | d10771d8k.htm |
| 2021-03-11 | 8-K | 2021-03-11 | 2.02 Results of Operations and Financial Condition | 2.02 On March 11, 2021, Zosano Pharma Corporation issued a press release titled “Zosano Pharma Reports Fourth Quarter and Fiscal Year 2020 Financial Results.” The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. | zsan-20210311.htm |
| 2021-03-11 | 8-K | 2021-03-08 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 8, 2021, John Walker, Chairman of the Board of Directors (the “Board”) of Zosano Pharma Corporation (the “Company”), delivered notice of his intention to retire from the Board effective as of, and not stand for reelection at, the upcoming annual meeting of shareholders, which is currently scheduled for June 10, 2021. | d112764d8k.htm |
| 2021-03-04 | 8-K | 2021-03-04 | 8.01 Other Events | 8.01 As previously reported, on November 12, 2020, Zosano Pharma Corporation (the “Company”) received a notice from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the Company was not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. | d100633d8k.htm |
| 2021-02-22 | 8-K | 2021-02-22 | 8.01 Other Events | 8.01 On February 22, 2021, Zosano Pharma Corporation issued a press release announcing the receipt of the official minutes from the U.S. Food and Drug Administration Division of Neurology II for the Type A meeting held on January 29, 2021 regarding the requirements for resubmission of the Qtrypta™ (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application following the Complete Response Letter received on October 20, 2020. | d64539d8k.htm |
| 2021-02-01 | 8-K | 2021-01-29 | 8.01 Other Events | 8.01 On February 1, 2021, Zosano Pharma Corporation issued a press release announcing that a Type A meeting with the U.S. Food and Drug Administration (“FDA”) was held on January 29, 2021, during which the Company and the FDA discussed the requirements for resubmission of the Qtrypta™ (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application following the complete response letter received on October 20, 2020. | d118525d8k.htm |
| 2021-01-06 | 8-K | 2021-01-06 | 8.01 Other Events | 8.01 On January 6, 2021, Zosano Pharma Corporation posted an updated corporate presentation to its website. | d107135d8k.htm |
| 2021-01-04 | 8-K | 2020-12-30 | 8.01 Other Events | 8.01 On January 4, 2021, Zosano Pharma Corporation issued a press release announcing that it has submitted a Type A meeting request to the U.S. Food and Drug Administration (“FDA”) to discuss the complete response letter received from the FDA in connection with the Qtrypta™ (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application. | d58826d8k.htm |